PURPOSE: To examine the effect of food on the oral bioavailability of a highly lipophilic, cannabinoid receptor agonist (CRA13) and to explore the basis for the food effect in lymph-cannulated and non-cannulated dogs. METHODS: Oral bioavailability was assessed in fasted and fed human volunteers and in lymph-cannulated dogs. In fasted dogs, the extent of absorption and oral bioavailability was also examined following administration of radiolabelled CRA13. RESULTS: Food had a substantial positive effect on the oral bioavailability of CRA13 in human volunteers (4.3-4.9 fold increase in AUC(0 - infinity)) and in dogs. The absolute bioavailability of parent drug was low in fasted dogs (8-20%), in spite of good absorption (72-75% of radiolabelled CRA13 recovered in the systemic circulation). In post-prandial lymph-cannulated dogs, bioavailability increased to 47.5% and the majority (43.7%) of the dose was absorbed via the intestinal lymphatic system. CONCLUSIONS: The positive food effect for CRA13 does not appear to result from increased post-prandial absorption. Rather these data provide one of the first examples of a significant increase in bioavailability for a highly lipophilic drug, which is stimulated via almost complete post-prandial transport into the lymph, in turn resulting in a reduction in first-pass metabolism.
PURPOSE: To examine the effect of food on the oral bioavailability of a highly lipophilic, cannabinoid receptor agonist (CRA13) and to explore the basis for the food effect in lymph-cannulated and non-cannulated dogs. METHODS: Oral bioavailability was assessed in fasted and fed human volunteers and in lymph-cannulated dogs. In fasted dogs, the extent of absorption and oral bioavailability was also examined following administration of radiolabelled CRA13. RESULTS: Food had a substantial positive effect on the oral bioavailability of CRA13 in human volunteers (4.3-4.9 fold increase in AUC(0 - infinity)) and in dogs. The absolute bioavailability of parent drug was low in fasted dogs (8-20%), in spite of good absorption (72-75% of radiolabelled CRA13 recovered in the systemic circulation). In post-prandial lymph-cannulated dogs, bioavailability increased to 47.5% and the majority (43.7%) of the dose was absorbed via the intestinal lymphatic system. CONCLUSIONS: The positive food effect for CRA13 does not appear to result from increased post-prandial absorption. Rather these data provide one of the first examples of a significant increase in bioavailability for a highly lipophilic drug, which is stimulated via almost complete post-prandial transport into the lymph, in turn resulting in a reduction in first-pass metabolism.
Authors: David M Shackleford; W A Faassen; Natalie Houwing; Holger Lass; Glenn A Edwards; Christopher J H Porter; William N Charman Journal: J Pharmacol Exp Ther Date: 2003-06-13 Impact factor: 4.030
Authors: Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter Journal: Pharm Res Date: 2013-02-21 Impact factor: 4.200
Authors: Gregory G Martin; Sarah Chung; Danilo Landrock; Kerstin K Landrock; Huan Huang; Lawrence J Dangott; Xiaoxue Peng; Martin Kaczocha; Drew R Seeger; Eric J Murphy; Mikhail Y Golovko; Ann B Kier; Friedhelm Schroeder Journal: J Neurochem Date: 2016-06-22 Impact factor: 5.372
Authors: Sifei Han; Luojuan Hu; Tim Quach; Jamie S Simpson; Natalie L Trevaskis; Christopher J H Porter Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: Huan Huang; Avery L McIntosh; Gregory G Martin; Danilo Landrock; Sarah Chung; Kerstin K Landrock; Lawrence J Dangott; Shengrong Li; Ann B Kier; Friedhelm Schroeder Journal: Biochemistry Date: 2016-09-02 Impact factor: 3.162
Authors: Gregory G Martin; Drew R Seeger; Avery L McIntosh; Sarah Chung; Sherrelle Milligan; Danilo Landrock; Lawrence J Dangott; Mikhail Y Golovko; Eric J Murphy; Ann B Kier; Friedhelm Schroeder Journal: Arch Biochem Biophys Date: 2018-05-12 Impact factor: 4.013